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BACKGROUND: Patients with chronic obstructive pul-
monary disease (COPD) are included in several national
pneumococcal vaccination recommendations whereas
asthma patients are not. The objective of this study was
to evaluate pneumonia-related hospitalization risk in
patients with COPD or asthma and vaccination impact.
METHODS: We identified patients with documented
pneumococcal vaccination from a cohort of veterans
with either a diagnosis of asthma or COPD and their
matched controls. Patients were identified between
October 1, 1997 and September 30, 1998 and followed
for 5 years. For each group we identified pneumococcal
pneumonia hospitalizations and all pneumonia-related
hospitalizations in the periods before and after vacci-
nation. We estimated hospitalization rates and com-
pared rates in the asthma and COPD groups to controls
using negative binomial regression models.
RESULTS: We identified 16,074 COPD patients (aver-
age age 65.8 years), 14,028 controls for the COPD
patients (average age 67.5 years), 2,746 asthma
patients (average age 53.0 years), and 1,345 controls
for the asthma patients (average age 59.2 years). Com-
pared to controls, the adjusted risk of pneumococcal
pneumonia hospitalizations before pneumococcal vac-
cination was COPD=8.02 (95% CI, 4.44–14.48) and
asthma=0.76 (0.17–3.53). For any pneumonia-related
hospitalization, the adjusted risk was COPD=3.91
(3.40–4.50) and asthma=1.45 (0.85–2.46). After vacci-
nation, events decreased in all groups. The adjusted
risk for pneumococcal pneumonia hospitalizations
postvaccination was COPD=3.87 (2.55–5.88) and
asthma=0.30 (0.04–1.99). For any pneumonia-related
hospitalization the adjusted risk was COPD=3.71
(3.33–4.13) and asthma=0.79 (0.50–1.25).
CONCLUSIONS: This study supports the value of
vaccinating COPD patients; however, the value of
vaccination for asthma patients is less certain.
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INTRODUCTION
The availability of pneumococcal vaccines makes pneumococ-
cal infections a common vaccine-preventable infection.
1 The
Centers for Disease Control and Prevention (CDC) have
recommended pneumococcal vaccination in the elderly and
others at high risk for serious pneumococcal infections and
their complications.
2 Evidence for these recommendations
ranges from high quality evidence of effectiveness to no
evidence of effectiveness. Despite the recommendations, pneu-
mococcal vaccination rates have historically been low for high-
risk individuals.
3,4
Patients with chronic obstructive pulmonary disease
(COPD) are considered high risk. However, persons with
asthma are not considered high-risk. Currently, there is a lack
of evidence of the burden of pneumococcal disease and the
effectiveness of the vaccination in patients with asthma. A
Cochrane review highlighted the lack of evidence of the efficacy
of pneumococcal vaccinations in asthma.
5
Talbot et al.
6 recently reported that patients with asthma are
at increased risk for pneumococcal disease. They found
patients with asthma had a 2.4-fold increase in pneumococcal
disease compared to those without asthma. Because asthma
prevalence continues to increase, it is important to determine
if patients with asthma should be included in pneumococcal
vaccination recommendations.
7 Inclusion of these patients in
the pneumococcal vaccination guidelines has the potential to
prevent a number of pneumococcal infections and attenuate
the burden of the disease, if asthma patients are at high risk.
However, the benefit would not outweigh costs of vaccination if
asthma patients are not at increased risk. Therefore, the
objective of this study is to determine the risk of pneumococcal
pneumonia and the impact of vaccination in adults with
asthma compared to a high-risk group (persons with COPD)
and the general population receiving care in the Veterans
Health Administration (VHA).
METHODS
We conducted a retrospective cohort study using national VHA
inpatient, outpatient, and mortality databases. We identified
patients with COPD or asthma and control patients for these
two groups, all of whom had documentation of pneumococcal
vaccination during the observation period. To understand the
potential impact of vaccination, we compared rates of pneu-
monia between patients with COPD or asthma and their
controls during two separate periods. Comparisons were made
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62in the prevaccination period (time period before receiving
pneumococcal vaccination) and the postvaccination period
(time period after receipt of pneumococcal vaccination) to
determine if risk was different between COPD and asthma
patients and controls during the two periods. We focused on
inpatient pneumonia diagnoses as events, as these are likely to
have a higher degree of accuracy for pneumococcal-specific
pneumonias than diagnoses in the outpatient setting, and we
would expect pneumococcal vaccinations to effect pneumococ-
cal pneumonia. Because not all pneumonias may be diagnosed
based on culture results, we compared three categories of
pneumonia: (1) pneumococcal, (2) pneumococcal or unspeci-
fied pneumonia, and (3) any pneumonia.
Cohort Identification
Four groups were identified: (1) COPD patients, (2) controls for
COPD patients, (3) asthma patients, and (4) controls for
asthma patients. Patients were eligible for inclusion if they
were receiving VHA care between October 1, 1997 and
September 30, 1998 (FY1998). To be included, patients had
to have at least one visit in FY1997 to ensure they were
receiving VHA health care services before the identification
year. Patients were excluded if they died within the first
6 months of FY1998. In this analysis, only patients with doc-
umentation of receiving a pneumococcal vaccination during
follow-up were included (Fig. 1).
COPD and Asthma Cohorts
Inclusion in the COPD or asthma cohorts was based on
presence of diagnostic codes in FY1998. Patients were required
to have two outpatient visits or one hospitalization with an
ICD-9 code for asthma or COPD. Patients were assigned to
either asthma only or COPD only based on the diagnosis codes
in FY1998 and excluded from the analysis if they had codes for
both. Patients were also excluded if diagnosis codes in FY1997
did not match group assignment in FY1998.
Controls
We created a probability-matched sample of controls for the
COPD and asthma patients. Control groups were matched to
disease groups on age, sex, and region of the country. Patients
were excluded from being controls if they had any diagnosis of
asthma or COPD in FY1997 or FY1998.
Follow-up Period
The disease and control populations were followed over the
same calendar time, which will account for secular trends
related to infection control practices, treatment, or pneumo-
nia risk that occurred over that period. The index visit was
the date of the first visit for asthma or COPD or the first visit
in FY1998 for the control patients. Patients were followed
Figure 1. Cohort identification process for patients included in the analysis.
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period (September 30, 2002). Person-time for each individual
was calculated in the prevaccination and postvaccination
period. The prevaccination person-time was the period from
index date to vaccination date. The postvaccination person-
time was the period from vaccination date until death or the
end of follow-up. For each pneumonia event a person
experienced during follow-up, 30 days were removed from
the individual’s person-time to avoid immortal time bias
because they were not at risk for another pneumonia event
during this time period based on how events were defined
(see below).
Pneumococcal Vaccination
Pneumococcal vaccinations were identified by procedure codes
(CPT or ICD-9 procedure code) during follow-up. The date the
code first appeared was defined as the vaccination date.
Event Identification
Cases of pneumonia were identified using inpatient diagnoses.
Pneumonias were categorized into three groups: (1) pneumo-
coccal (ICD-9 481), (2) pneumococcal or unspecified pneumo-
nia (ICD-9 481, 485, and 486), and (3) any pneumonia (ICD-9
481–486). For each pneumonia event identified, the date of the
first appearing diagnostic code was the event index date. To
avoid double-counting cases when follow-up care was being
provided, we excluded events appearing within 30 days after
the event index date. These were considered an extension of
the initial event.
Analysis
For each patient, we used data from their index visit to describe
baseline characteristics (age, sex, race, and region). To assess
comorbidities and baseline health care utilization, we used the
Table 1. Baseline Characteristics of Patients Included in the Analysis
COPD Controls P value Asthma Controls P value
N 16,074 14,028 2,746 1,345
Year of vaccination, N (%) <0.001 0.274
1998 5,367 (33.4) 4,020 (28.7) 742 (27.0) 337 (25.1)
1999 3,120 (19.4) 2,684 (19.1) 503 (18.3) 274 (20.4)
2000 2,694 (16.8) 2,461 (17.5) 479 (17.4) 254 (18.9)
2001 2,820 (17.5) 2,774 (19.8) 572 (20.8) 263 (19.6)
2002 2,073 (12.9) 2,089 (14.9) 450 (16.4) 217 (16.1)
Sex, N (%)
Male 15,714 (97.8) 13,859 (98.8) 2,423 (88.2) 1,289 (95.8)
Age group, N (%)
≤34 31 (0.2) 7 (0.1) 269 (9.8) 41 (3.1)
35–44 349 (2.4) 118 (0.8) 575 (20.9) 151 (11.2)
45–54 2,227 (13.9) 1,137 (8.1) 720 (26.2) 328 (24.4)
55–64 3,774 (23.5) 3,256 (23.2) 474 (17.3) 282 (21.0)
65–74 6,365 (69.6) 6,267 (44.7) 510 (18.6) 385 (28.6)
≥75 3,328 (20.7) 3,243 (23.1) 198 (7.2) 158 (11.8)
Age, avg. (SD) 65.8 (10.1) 67.5 (9.1) 53.0 (14.2) 59.2 (13.1)
Race, N (%) <.001 0.003
White 10,664 (66.3) 7,344 (52.4) 1,105 (40.2) 607 (45.1)
Black 1,516 (9.4) 1,792 (12.8) 410 (14.9) 171 (12.7)
Others 549 (3.5) 701 (4.9) 329 (12.1) 192 (14.3)
Unknown 3,345 (20.8) 4,191 (29.9) 902 (32.9) 375 (27.9)
Comorbidities, N (%)
HTN 6,605 (41.1) 7,029 (50.1) <0.001 805 (29.3) 582 (43.3) <0.001
IHD 1,476 (9.2) 985 (7.0) <0.001 101 (3.7) 95 (7.1) <0.001
Arthritis 2,760 (17.2) 2,338 (16.7) 0.250 333 (12.1) 192 (14.3) 0.054
Diabetes 2,239 (13.9) 3,157 (22.5) <0.001 247 (9.0) 282 (21.0) <0.001
Psych 1,550 (9.6) 920 (6.6) <0.001 288 (10.5) 150 (11.2) 0.519
SA 327 (2.0) 162 (1.2) <0.001 101 (3.7) 56 (4.2) 0.447
Dep 431 (2.7) 256 (1.8) <0.001 97 (3.5) 34 (2.5) 0.087
Cancer 3,223 (20.1) 2,399 (17.1) <0.001 288 (10.5) 161 (12.0) 0.154
Alcohol 1,225 (7.6) 566 (4.0) <0.001 153 (5.6) 92 (6.8) 0.108
HF 1,859 (11.6) 706 (5.0) <0.001 48 (1.8) 50 (3.7) <0.001
AIDS/HIV 42 (0.3) 46 (0.3) 0.285 10 (0.4) 24 (1.8) <0.001
Disease-related utilization, avg. (SD)
Hosp 0.32 (0.8) 0.005 (0.1)
ED visits 0.28 (0.9) 0.007 (0.1)
Outpt 2.85 (4.6) 0.050 (0.3)
Overall health care utilization, avg. (SD)
Hosp 0.45 (1.0) 0.20 (0.6) <0.001 0.18 (0.6) 0.23 (0.9) 0.060
ED visits 0.92 (2.0) 0.42 (1.2) <0.001 0.84 (1.8) 0.46 (1.2) <0.001
Outpt 20.62 (22.7) 14.54 (18.3) <0.001 18.33 (21.8) 15.56 (22.8) <0.001
Comorbidities: HTN=hypertension, IHD=ischemic heart disease, Psych=psychoses, SA=substance abuse, Dep=depression, Alcohol=alcoholism, HF=
heart failure.
Health care utilization: Hosp=hospitalizations, Outpt=outpatient contacts, ED=emergency department.
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for each patient was defined as the annual number of hospital-
izations, emergency department (ED) visits and outpatient
visits. For the disease groups, we determined the annual rate
of disease-related health care utilization. For each disease
category, we compared baseline variables using χ
2 tests for
categorical variables and t tests for continuous variables.
For disease groups and controls, we estimated pneumonia-
related hospitalization rates in prevaccination and postvacci-
nation periods. We used negative binomial models to compare
adjusted relative risk between the disease group and controls
in the prevaccination and postvaccination periods. Negative
binomial models were used because the rates represent a
nonnegative count function with overdispersion.
8–11 Models
were adjusted for age, sex, comorbidities (each of 11 comorbid-
ities included as a dichotomous variable), and baseline health
care utilization.
RESULTS
The proportion of patients with pneumococcal vaccination
during follow-up was 16.8% in the COPD group, 14.7% in the
COPD controls, 22.7% in the asthma group, and 11.1% in the
asthma control group. This resulted in 16,074 patients with
COPD and 14,028 COPD controls that were included in the
analysis (Fig. 1). There were 2,746 patients with asthma and
1,345 asthma controls included.
The characteristics of patients included are shown in
Table 1. The largest percentage in each group was vaccinated
in 1998; however, the percentage was between 15% and 20%
in each subsequent year. In the asthma group, a higher
percentage of the disease group vaccinated was females com-
pared to controls (11.8% vs 4.2%). The average age of controls
was higher than the disease group.
Compared to patients excluded from the analysis, the
patients with vaccinations during follow-up were older in each
of the groups with the exception of the COPD disease group.
The patients in the analysis were similar to those excluded
with respect to baseline ED visits and outpatient visits. The
patients excluded (i.e., no vaccination during follow-up) had
higher rates of hospitalization than those included.
Prevaccination and postvaccination follow-up times were
similar between disease groups and controls (Table 2). Rates of
pneumonia-related hospitalizations occurring during prevac-
cination and postvaccination periods are shown in Table 3. The
rate of pneumococcal pneumonia-related hospitalizations de-
creased in COPD patients from 0.47 per 100 person-years in
the prevaccination period to 0.37 per 100 person-years in the
postvaccination period. The COPD controls had a small
increase in rates from 0.05 cases per 100 person-years pre-
vaccination to 0.08 cases per 100 person-years postvaccina-
tion. The adjusted relative risk between the COPD patients and
controls went from 8.02 (95% CI 4.44 to 14.48) in the
prevaccination period to 3.87 (95% CI 2.55 to 5.88) in the
postvaccination period.
The rates of pneumococcal or unspecified pneumonia
hospitalizations increased in both the COPD and control group
from prevaccination to postvaccination periods (Table 3). The
adjusted relative risk for pneumococcal or unspecified pneu-
monia hospitalizations for COPD patients compared to con-
trols was similar in the prevaccination and postvaccination
periods (3.84 [95% CI 3.31 to 4.45] vs 3.61 [95% CI 3.22 to
4.05]).
For asthma patients and controls, the rate of pneumococcal
pneumonia-related hospitalizations decreased from prevacci-
Table 2. Follow-up Time and Mortality Rate in COPD and Asthma Groups
COPD Asthma
COPD Controls Asthma Controls
Duration of follow-up (y), mean (SD)
Prevaccination 1.86 (1.46) 1.99 (1.47) 2.12 (1.48) 2.10 (1.47)
Postvaccination 2.53 (1.47) 2.59 (1.47) 2.64 (1.47) 2.55 (1.46)
Mortality, N (%)
Died 1,591 (11.3) 3,718 (23.1) 86 (6.4) 105 (3.8)
Table 3. Pneumonia-Related Hospitalization Rates During Follow-up
by Disease Group in the Vaccinated Cohort (Rates Presented per
100 Person-Years)
Crude rates per
100 person-y
Adjusted
relative
risk
95% CI
Disease
group
Controls
COPD
Pneumococcal pneumonia only
Prevaccination 0.47 0.05 8.02 4.44 to 14.48
Postvaccination 0.37 0.08 3.87 2.55 to 5.88
Pneumococcal and unspecified pneumonias
Prevaccination 4.83 0.91 3.84 3.31 to 4.45
Postvaccination 5.90 1.39 3.61 3.22 to 4.05
Any pneumonia
Prevaccination 5.77 1.06 3.91 3.40 to 4.50
Postvaccination 7.07 1.62 3.71 3.33 to 4.13
Overall hospitalizations
Prevaccination 64.71 52.00
Postvaccination 45.64 23.72
Asthma
Pneumococcal pneumonia only
Prevaccination 0.09 0.21 0.76 0.17 to 3.53
Postvaccination 0.03 0.09 0.30 0.04 to 1.99
Pneumococcal or unspecified pneumonia
Prevaccination 1.11 0.70 1.78 0.97 to 3.26
Postvaccination 0.99 1.17 0.81 0.50 to 1.31
Any pneumonia
Prevaccination 1.27 0.99 1.45 0.85 to 2.46
Postvaccination 1.11 1.34 0.79 0.50 to 1.25
Overall hospitalizations
Prevaccination 49.59 52.79
Postvaccination 17.75 22.17
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than in COPD patients. Furthermore, there were no significant
differences in the relative risk of pneumonia between asthma
patients and controls in either the prevaccination period or
postvaccination period.
DISCUSSION
The aim of this study was to evaluate the impact of pneumo-
coccal vaccination on rates of pneumonia-related hospitaliza-
tions in patients with COPD and asthma relative to patients
without those respiratory diseases. COPD patients with a
vaccination had decreased rates of pneumococcal pneumonia
hospitalizations after vaccination. However, they still had
nearly a fourfold increase in the risk of pneumococcal pneu-
monia hospitalizations compared to control patients. The rates
of pneumococcal pneumonia hospitalizations were also lower
in asthma patients after vaccination. But unlike with COPD,
the adjusted relative risk of pneumococcal pneumonia hospi-
talizations for asthma patients was not significantly different
from controls.
Our findings support the observation that patients with
COPD have a substantially elevated risk of pneumococcal
pneumonia-related hospitalizations. Pneumococcal vaccina-
tion reduces the magnitude of the increased risk; however,
risk remains elevated in COPD patients compared to similar
patients without COPD. The results in the asthma analysis are
different. Asthma patients did not have a higher risk of
pneumococcal pneumonia than similar patients without asth-
ma. The risk for pneumococcal pneumonia in asthma patients
is not different from control patients, and the rate in asthma
patients is much lower than in patients with COPD.
With respect to the rate of pneumonia in patients with
asthma relative to controls, our findings are in contrast to
results recently reported by Talbot et al.
6 They found persons
with asthma had a 2.4-fold increased risk of invasive pneu-
mococcal disease compared to controls. Before receiving a
vaccination, we found the rate of pneumococcal pneumonia
was lower in asthma patients than controls. For pneumococcal
plus unspecified pneumonias the rate in the asthma group
was 1.78 times higher than controls and for all pneumonias
was 1.45 times higher than controls; however, neither was
statistically significant. There are substantial differences be-
tween the two studies that could account for the differences.
Talbot et al. focused on invasive pneumococcal disease while
we focused solely on pneumonias as a potentially serious
complication in those with chronic respiratory disease. In
addition, Talbot et al. used identification of pneumococcal
events in a focused surveillance program while we relied on
administrative data. Finally, the ages of the asthma patients
studied are different, the average age in the Talbot et al.
analysis was 28.5 years and in our asthma population it was
53.0 years. Thus, it may not be surprising that differences
exist in the results from the two studies.
The benefit of pneumococcal vaccination has been studied
in both randomized trials and observational studies. There
have been several meta-analyses that summarize the results of
randomized trials.
12–16 The results of some of these meta-
analyses find no benefit for pneumococcal vaccination in the
elderly or other high-risk populations.
12,13,15,16 When obser-
vational studies in the elderly or those with chronic disease
were systematically reviewed, the use of pneumococcal vaccine
was associated with a 32% reduction in the risk of all-cause
pneumonia.
17 Observational studies provide evidence for the
effectiveness of pneumococcal vaccination in high-risk popula-
tions. Unlike previous studies (other than those in HIV
patients), our study focused on a specific subset of patients
included in vaccination recommendations (COPD patients)
and compared the findings in those patients with results from
patients that may also be at an elevated risk for pneumococcal
pneumonia and could potentially benefit from vaccination.
There are limitations that need to be acknowledged. First,
this is an observational study that utilizes administrative data
in identifying the cohort and the presence of pneumococcal
vaccination and pneumonia-related hospitalizations. The in-
terpretation of the results is impacted by the validity and
accuracy of diagnoses in administrative data. The validity of
COPD and asthma diagnoses has varied across administrative
databases
18–21 and we have found that 80.8%, from a sample
of 120 patients with a diagnosis of COPD in the VHA system,
had lung function tests consistent with the diagnosis (unpub-
lished data). To reduce diagnostic misclassification, we used a
definition of two rather than one outpatient diagnosis or one
inpatient diagnosis. Yet, some patients included in the disease
groups may not have either COPD or asthma, but it is likely
that they have symptoms and complaints consistent with the
disease and would be considered clinically as having the dis-
ease. In this light, it is important to consider that the decision
to recommend pneumococcal vaccination to a patient if they
fall into a high-risk group will most likely be based on
diagnoses reported in the patient’s records, their self-reported
diagnoses, or their symptoms and not the result of lung
function tests to confirm the patient has either COPD or
asthma. Therefore, these results provide a “real world” look at
the effectiveness of pneumococcal vaccination in patients with
diagnoses of COPD or asthma.
It is also important to consider the validity of pneumonia
diagnoses. We were unable to confirm diagnoses through
culture results and rely on the accuracy of the diagnosis in
administrative data. However, because not all pneumonias
may be diagnosed based on culture results we considered
three separate end points. Previous observational studies have
looked at all-cause pneumonias as the outcome rather than
focusing on pneumococcal pneumonia specifically.
17 We felt
examining pneumococcal pneumonias specifically was impor-
tant because that is where we expect to see the most effect and
by limiting the analysis to hospitalizations the likelihood of the
diagnosis being based on culture results is higher than using
outpatient diagnoses.
Because this is an observational study and patients were
not randomized to receive pneumococcal vaccination, there
may be selection bias involved in choosing patients for
vaccination. That is, the vaccinated patients are likely to be
different from the unvaccinated patients.
22 By focusing solely
on patients vaccinated, we remove concerns about selection
bias between vaccinated and nonvaccinated patients and are
still able to compare the relative impact of pneumococcal
pneumonia within disease groups and attempt to control for
any remaining differences using regression models. We relied
on the presence of vaccination codes in administrative data-
bases to identify our vaccinated subgroups. It is possible for
pneumococcal vaccines to be administered in several settings
and documentation of vaccination in the medical record may
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vaccination and Weaver et al.
23 have shown in a sample of
VHA patients that more than 80% of those that had a code for
vaccination in the administrative data reported receiving
pneumococcal vaccination.
Another issue with reliance on administrative data to
identify vaccinations is the date of vaccination. We used the
first code for a vaccination that appeared during the follow-up
to define the date of vaccination. It is possible that in some
cases the date the code appeared in the administrative data is
not reflective of the actual vaccination administration date. If
this were true, patients would actually have been vaccinated in
the prevaccination period. However, there would be no reason
to believe that such misclassification of exposure date would
be differential between disease and control groups. Even if
differential misclassification existed, we would presumably be
seeing lower rates of events in the prevaccination period than if
all patients had not been vaccinated during this period.
Therefore, our estimate of the benefit of vaccination would be
a lower (conservative) estimate of the benefit of vaccinating
patients in these groups.
One needs to be cautious when drawing conclusions about
the benefit of an intervention when studied in a naturalistic
setting and pre- and postcomparisons are made. There is
concern that results may be an ecological fallacy because of
several factors and cannot be attributed to pneumococcal
vaccination. In this study, we are following a group of
patients with chronic respiratory disease that is aging over
the time period. We would expect increases in rates of
pneumonias over the time period as the diseases progress
and the cohort ages. However, our results show that rates of
pneumococcal events decreased in each group after vaccina-
tion administration. It would be difficult not to conclude that
vaccination had an impact and simply explain the results
away as an ecological fallacy. Finally, because the subset of
patients included in the analysis represents the minority of
patients initially identified, it is unclear whether these
findings would apply to the entire population with COPD or
asthma.
In conclusion, our study showed that pneumococcal
pneumonia produces substantial disease burden in patients
with COPD. The use of pneumococcal vaccination can reduce
that burden, but the rate of events still remains higher than
in similar patients without COPD. In asthma patients, the
rates of pneumococcal events were much lower than in COPD
patients. But similar to COPD patients, the rate of pneumo-
coccal hospitalizations decreased in patients that received a
pneumococcal vaccination. Importantly, the rates were not
different from similar patients without asthma. This study
supports the value of vaccinating COPD patients and their
inclusion in pneumococcal vaccination recommendations;
however, the value of vaccination for asthma patients is less
certain and it may not make sense to include them as a high-
risk group simply based on an asthma diagnosis.
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